when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

1,710 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT825 Endpoints630 BioPharma Dive241 onclive165 Fierce Biotech91 BioSpace90 raps32 globenewswire health28 fda recalls

therapy area

all Oncology574 Rare Disease284 Immunology229 Cardiology193 Hematology159 Pulmonology131 Vaccines99

Clinical Implementation and Surveillance Strategies
onclive · 2mo ago↗ source
Case Introduction and ctDNA as Emerging Risk Factor
onclive · 2mo ago↗ source
How Penn Medicine plans to use AI to train their doctors
Physicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...
Endpoints · 2mo ago↗ source

page 48 of 69

22

Psychiatry & CNS87

Ophthalmology86

Endocrinology & Metabolism52

ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

onclive · 2mo ago↗ source

MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies

Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.

onclive · 2mo ago↗ source

Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

onclive · 2mo ago↗ source

HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response

HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.

onclive · 2mo ago↗ source

Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)

Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.

onclive · 2mo ago↗ source

Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss

How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.

onclive · 2mo ago↗ source

STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns

The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds

STAT · 2mo ago↗ source

Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

Here we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at…

Endpoints · 2mo ago↗ source

STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

STAT · 2mo ago↗ source

Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval

Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to com…

Endpoints · 2mo ago↗ source

STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.

STAT · 2mo ago↗ source

STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.

STAT · 2mo ago↗ source

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

BeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…

Endpoints · 2mo ago↗ source

STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the agency.

STAT · 2mo ago↗ source

STAT+: Treatment for alcohol addiction is undergoing a seismic shift. Many say it’s overdue

The surging popularity of alternatives to Alcoholics Anonymous represents a seismic shift in the alcohol treatment landscape. Many say it's overdue.

STAT · 2mo ago↗ source

Opinion: Using AI in addiction medicine could be particularly risky

"AI can make great strides in medical decision support, but unfiltered interaction between agent and patient is dangerous," writes Steve D. Klein.

STAT · 2mo ago↗ source

Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer

Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.

onclive · 2mo ago↗ source

Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies

Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.

onclive · 2mo ago↗ source

Hantavirus risk remains low, CDC says, citing its ‘playbook’ response

Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low.

STAT · 2mo ago↗ source

Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

onclive · 2mo ago↗ source

Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud

Vice President JD Vance announced a $1.3 billion deferral in Medicaid reimbursements to California, as part of an initiative to root out fraud in federal health programs.

STAT · 2mo ago↗ source

Opinion: The hantavirus is a wake-up call. Will the Trump administration answer it?

Arriving in the isolation ward of a biocontainment hospital is an unsettling, scary experience. In 2014, I spent 19 days in one while being treated for Ebola, watching the news…

STAT · 2mo ago↗ source